In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.
Stanford scientists, using only direct brain stimulation, reproduced both the brain dynamics and the behavioral response of mice taught to discriminate between two different images.
A large multicenter clinical trial led by Stanford physician Tait Shanafelt, MD, indicates that people with chronic lymphocytic leukemia may forgo chemotherapy in favor of new, targeted treatments.
Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.
Cancer cells are known to protect themselves using proteins that tell immune cells not to attack them. Stanford researchers have discovered a new “don’t eat me” signal, and blocking it may make cancer cells vulnerable to attack by the immune system.
In a Stanford study, 79 percent of preschoolers with attention-deficit hyperactivity disorder were not ready for school, compared with 13 percent of other children.
When surveyors from The Joint Commission conducted their triennial accreditation survey earlier this summer, Stanford Health Care passed with flying colors.
